Real-World Accuracy of Continuous Glucose Monitoring During Intensive Hematological Care: A Prospective Study
Authors' conclusion
Despite the relative high MARD, the use of CGM is unlikely to result in harmful insulin dosing errors and seems feasible to use during intensive hematological care.
Study context
- Population
- Adults hospitalized for intensive hematological care (CAR-T, allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT)); 28% female, median age 64 [58–68] years, 10% with history of DM
- Participants
- 60 adults1,999 matched pairs
- Comparison
- CGM vs capillary point-of-care glucose measurements
- Outcome
- CGM accuracy vs POC: mean and median absolute relative difference (MARD), DTS Error Grid, % values within 15%/15, 20%/20 and 30%/30 mg/dL
Methodological detailsconcurrent CGM and capillary point-of-care (POC) measurements
- Concurrent CGM and capillary POC measurements
Performance
As reported in the abstract
CGM accuracy vs POC
- Overall mean ARD
- 21.5%
- Within 15%/15 mg/dL
- 38.1%
- Within 20%/20 mg/dL
- 51.1%
- Within 30%/30 mg/dL
- 75.1%
- Diabetes Technology Society (DTS) Error Grid pairs within zone A + B
- 99.6%
Original publication
Real-World Accuracy of Continuous Glucose Monitoring During Intensive Hematological Care: A Prospective Study. Diabetes Technol Ther. Published 2 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →